Jump to content
RemedySpot.com

ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML

Rate this topic


Guest guest

Recommended Posts

Guest guest

MolecularMD was founded by Druker.

Zavie

News from Business Wire

This press release was issued via BusinessWire.com. Go to

www.BusinessWire.com <http://www.businesswire.com> for additional news -

registration<http://www.businesswire.com/portal/site/home/index.jsp?epi-content=\

BW_WIZARD_POPUP_TYPE & beanStrID=bwprofile & wizardName=userreg & viewID=MY_PORTAL_VIE\

W & redirectURL=/portal/site/home/>is

free and quick!

March 28, 2011 07:35 AM Eastern Daylight Time

ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test

for The T315I BCR-ABL Mutation in Patients With

CML<http://www.businesswire.com/news/home/20110328005408/en/ARIAD-MolecularMD-An\

nounce-Collaboration-Companion-Diagnostic-Test>

<http://www.businesswire.com/news/home/20110328005408/en/ARIAD-MolecularMD-Annou\

nce-Collaboration-Companion-Diagnostic-Test>CAMBRIDGE,

Mass. & PORTLAND, Ore.--(BUSINESS WIRE)--ARIAD

Pharmaceuticals, Inc.

<http://cts.businesswire.com/ct/CT?id=smartlink & url=http%3A%2F%2Fwww.ariad.com%2\

F & esheet=6660914 & lan=en-US & anchor=ARIAD+Pharmaceuticals%2C+Inc.+ & index=1 & md5=0af\

6f3d1c751b2bfb62b2828e389fa23>(NASDAQ:

ARIA) and MolecularMD Corporation today announced an exclusive collaboration

agreement in which MolecularMD will develop and commercialize a companion

diagnostic test to identify the T315I mutation of the BCR-ABL gene in

patients with chronic myeloid leukemia (CML) and Philadelphia positive (Ph+)

acute lymphoblastic leukemia (ALL).

ARIAD is advancing its investigational, pan-BCR-ABL inhibitor, ponatinib, in

the pivotal PACE trial of patients with resistant or intolerant CML and Ph+

ALL, or those with the T315I mutation. MolecularMD has performed BCR-ABL

mutation testing with its standardized and validated sequencing test in

patients enrolled in ARIAD’s earlier Phase 1 trial of ponatinib and now is

cond...

*Read the full news release on BusinessWire.com

*<http://www.businesswire.com/news/home/20110328005408/en/ARIAD-MolecularMD-Anno\

unce-Collaboration-Companion-Diagnostic-Test>

Business Wire features breaking news from leading companies and

organizations worldwide. We invite you to set up your free news profile

personalized to your interests. Register now at

www.BusinessWire.com<http://www.businesswire.com>

..

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...